GLEN ROCK, N.J., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company"), a leader in developing drugs for respiratory disorders, particularly drug-induced respiratory depression as well as obstructive, central and mixed sleep apneas, announces that it will be participating in and presenting at the 7th Annual Biotech Showcase 2015™ being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 – 15, 2015. The Company will be providing additional information with respect to its presentation at this event in early 2015.
In addition to presenting, Cortex will be conducting one-on-one meetings with current and prospective investors and will be participating in the partnering program. The partnering program is powered by partneringONE®, an industry-specific meeting system, that will enable the Company to identify and arrange meetings with potential investors and business development prospects. There is also an extensive program of workshops and other events in which the Company will attend and participate.
Because it is independent and not sell-side related, Biotech Showcase™ is considered to be one of the premier life science events taking place during what many consider to be the most important week of the year for healthcare companies and their investors. This event will provide the Company with the opportunity to meet directly with life science industry-specific investors, other institutional investors, and with pharmaceutical business development executives.
Biotech Showcase™ is co-produced by Demy-Colton Life Science Advisors and EBD Group. In 2014, this event attracted 1,700 attendees and 242 corporate presentations.
About Cortex Pharmaceuticals, Inc.
Cortex Pharmaceuticals, Inc. is a biopharmaceutical company currently engaged in the discovery and development of drugs for the treatment of respiratory disorders. Drug candidates are currently derived from two platforms, as described below.
The first platform is a class of compounds known as ampakines that act as positive allosteric modulators of AMPA glutamate receptors. Several ampakines in both oral and injectable form are being developed by Cortex for the treatment of drug induced respiratory depression caused by opiates and anesthetics. In preclinical and clinical studies, such drugs have shown preliminary efficacy in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects of drugs such as propofol. The Company's compounds belong to a new generation of ampakines that do not display the undesirable side effects displayed by previous compounds.
The second platform involves the class of compounds known as cannabinoids, in particular, dronabinol. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol significantly improved measures of sleep apnea in a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B study is currently being conducted at the University of Illinois and is being funded by the National Institutes of Health.
Additional information about Cortex and the matters discussed herein can be obtained on the Company's web-site at www.cortexpharm.com or in the Company's filings on EDGAR at www.sec.gov.
Special Note Regarding Forward-Looking Statements
Certain statements included or incorporated by reference in this news release, including information as to the future financial or operating performance of the Company and its drug development programs, constitute forward-looking statements. The words "believe," "expect," "anticipate," "contemplate," "target," "plan," "intend," "continue," "budget," "estimate," "may," "schedule" and similar expressions identify forward-looking statements. Forward-looking statements include, among other things, statements regarding future plans, targets, estimates and assumptions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Many factors could cause the Company's actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, the Company. Due to these various risks and uncertainties, actual events may differ materially from current expectations. Investors are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward looking statements due to the inherent uncertainty therein. Forward-looking statements are made as of the date of this news release and the Company disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or results or otherwise.